These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 38473786)

  • 41. RB loss contributes to aggressive tumor phenotypes in MYC-driven triple negative breast cancer.
    Knudsen ES; McClendon AK; Franco J; Ertel A; Fortina P; Witkiewicz AK
    Cell Cycle; 2015; 14(1):109-22. PubMed ID: 25602521
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pharmacotranscriptomic profiling of resistant triple-negative breast cancer cells treated with lapatinib and berberine shows upregulation of PI3K/Akt signaling under cytotoxic stress.
    Jabbarzadeh Kaboli P; Luo S; Chen Y; Jomhori M; Imani S; Xiang S; Wu Z; Li M; Shen J; Zhao Y; Wu X; Hin Cho C; Xiao Z
    Gene; 2022 Mar; 816():146171. PubMed ID: 35026293
    [TBL] [Abstract][Full Text] [Related]  

  • 43. PIM1 kinase inhibition as a targeted therapy against triple-negative breast tumors with elevated MYC expression.
    Horiuchi D; Camarda R; Zhou AY; Yau C; Momcilovic O; Balakrishnan S; Corella AN; Eyob H; Kessenbrock K; Lawson DA; Marsh LA; Anderton BN; Rohrberg J; Kunder R; Bazarov AV; Yaswen P; McManus MT; Rugo HS; Werb Z; Goga A
    Nat Med; 2016 Nov; 22(11):1321-1329. PubMed ID: 27775705
    [TBL] [Abstract][Full Text] [Related]  

  • 44. High Myc expression and transcription activity underlies intra-tumoral heterogeneity in triple-negative breast cancer.
    Gupta N; Jung K; Wu C; Alshareef A; Alqahtani H; Damaraju S; Mackey JR; Ghosh S; Sabri S; Abdulkarim BS; Bigras G; Lai R
    Oncotarget; 2017 Apr; 8(17):28101-28115. PubMed ID: 28427212
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Rearrangements, Expression, and Clinical Significance of MYB and MYBL1 in Adenoid Cystic Carcinoma: A Multi-Institutional Study.
    Persson M; Andersson MK; Mitani Y; Brandwein-Weber MS; Frierson HF; Moskaluk C; Fonseca I; Ferrarotto R; Boecker W; Loening T; El-Naggar AK; Stenman G
    Cancers (Basel); 2022 Jul; 14(15):. PubMed ID: 35954356
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
    Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
    Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer.
    Yan S; Dey P; Ziegler Y; Jiao X; Kim SH; Katzenellenbogen JA; Katzenellenbogen BS
    Breast Cancer Res Treat; 2021 Jan; 185(2):281-292. PubMed ID: 33001337
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Silibinin induces metabolic crisis in triple-negative breast cancer cells by modulating EGFR-MYC-TXNIP axis: potential therapeutic implications.
    Iqbal MA; Chattopadhyay S; Siddiqui FA; Ur Rehman A; Siddiqui S; Prakasam G; Khan A; Sultana S; Bamezai RN
    FEBS J; 2021 Jan; 288(2):471-485. PubMed ID: 32356386
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Metabolic reprogramming in triple-negative breast cancer through Myc suppression of TXNIP.
    Shen L; O'Shea JM; Kaadige MR; Cunha S; Wilde BR; Cohen AL; Welm AL; Ayer DE
    Proc Natl Acad Sci U S A; 2015 Apr; 112(17):5425-30. PubMed ID: 25870263
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Epigenomic Profiling Advises Therapeutic Potential of Leukotriene Receptor Inhibitors for a Subset of Triple-Negative Breast Tumors.
    Kalinkin AI; Sigin VO; Kuznetsova EB; Ignatova EO; Vinogradov II; Vinogradov MI; Vinogradov IY; Zaletaev DV; Nemtsova MV; Kutsev SI; Tanas AS; Strelnikov VV
    Int J Mol Sci; 2023 Dec; 24(24):. PubMed ID: 38139172
    [TBL] [Abstract][Full Text] [Related]  

  • 51. MYC-driven U2SURP regulates alternative splicing of SAT1 to promote triple-negative breast cancer progression.
    Deng L; Liao L; Zhang YL; Hu SY; Yang SY; Ma XY; Huang MY; Zhang FL; Li DQ
    Cancer Lett; 2023 Apr; 560():216124. PubMed ID: 36907504
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Gene network analysis using SWIM reveals interplay between the transcription factor-encoding genes HMGA1, FOXM1, and MYBL2 in triple-negative breast cancer.
    Fiscon G; Pegoraro S; Conte F; Manfioletti G; Paci P
    FEBS Lett; 2021 Jun; 595(11):1569-1586. PubMed ID: 33835503
    [TBL] [Abstract][Full Text] [Related]  

  • 53. miR‑574‑5p attenuates proliferation, migration and EMT in triple‑negative breast cancer cells by targeting BCL11A and SOX2 to inhibit the SKIL/TAZ/CTGF axis.
    Zhang KJ; Hu Y; Luo N; Li X; Chen FY; Yuan JQ; Guo L
    Int J Oncol; 2020 May; 56(5):1240-1251. PubMed ID: 32319565
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Problematic breast tumors reassessed in light of novel molecular data.
    Pareja F; Weigelt B; Reis-Filho JS
    Mod Pathol; 2021 Jan; 34(Suppl 1):38-47. PubMed ID: 33024304
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New substituted quinoxalines inhibit triple-negative breast cancer by specifically downregulating the c-MYC transcription.
    Hu MH; Wu TY; Huang Q; Jin G
    Nucleic Acids Res; 2019 Nov; 47(20):10529-10542. PubMed ID: 31584090
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Block of proliferation 1 (BOP1) plays an oncogenic role in hepatocellular carcinoma by promoting epithelial-to-mesenchymal transition.
    Chung KY; Cheng IK; Ching AK; Chu JH; Lai PB; Wong N
    Hepatology; 2011 Jul; 54(1):307-18. PubMed ID: 21520196
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunohistochemical signaling pathways of triple negative and triple positive breast cancers: What is new?
    Elsers DA; Masoud EM; Kamel NAMH; Ahmed AM
    Ann Diagn Pathol; 2021 Dec; 55():151831. PubMed ID: 34634762
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Integrative analysis of genomic amplification-dependent expression and loss-of-function screen identifies ASAP1 as a driver gene in triple-negative breast cancer progression.
    He J; McLaughlin RP; van der Beek L; Canisius S; Wessels L; Smid M; Martens JWM; Foekens JA; Zhang Y; van de Water B
    Oncogene; 2020 May; 39(20):4118-4131. PubMed ID: 32235890
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Targeting SET to restore PP2A activity disrupts an oncogenic CIP2A-feedforward loop and impairs triple negative breast cancer progression.
    Liu CY; Huang TT; Chen YT; Chen JL; Chu PY; Huang CT; Wang WL; Lau KY; Dai MS; Shiau CW; Tseng LM
    EBioMedicine; 2019 Feb; 40():263-275. PubMed ID: 30651219
    [TBL] [Abstract][Full Text] [Related]  

  • 60. MYB RNA In Situ Hybridization Is a Useful Diagnostic Tool to Distinguish Breast Adenoid Cystic Carcinoma From Other Triple-negative Breast Carcinomas.
    Butcher MR; White MJ; Rooper LM; Argani P; Cimino-Mathews A
    Am J Surg Pathol; 2022 Jul; 46(7):878-888. PubMed ID: 35522890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.